Colin Davidson

Prof. Colin Davidson


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2001 in Brain Research Reviews
Verified
Journal Article
Closed access
CDColin Davidson
Colin Davidson
AGAndrew Gow
Andrew Gow
TLTong H. Lee
Tong H. Lee
EEEverett H. Ellinwood
Everett H. Ellinwood

1 March 1995 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
CDColin Davidson
Colin Davidson
JSJonathan A. Stamford
Jonathan A. Stamford
Electrically stimulated 5‐hydroxytryptamine (5‐HT) release was monitored in slices of rat dorsal raphé nucleus (DRN) by fast cylic voltammetry. Pseudo‐single pulse stimulations (5 pulses at 100 Hz) were used to enable the effect of various receptor agonists to be seen without competition from endogenously released transmitter. The selective 5‐HT1A receptor agonist, (+)‐8‐OH‐DPAT (1.0 μm) decreased stimulated 5‐HT release to 31 ± 3% of controls. This decrease was inhibited by the 5‐HT1A receptor antagonists, (+)‐WAY‐100135 (1.0 μm) and WAY‐100635 (0.1 μm) but not by the 5‐HT1D/B antagonist, GR127935 (0.05 μm). The selective 5‐HT1B receptor agonist, CP‐93129 (0.3 μm) decreased stimulated 5‐HT release to 61 ± 4% of control. This effect was antagonized by the 5‐HT1B receptor antagonist, isamoltane (0.5 μm) but not by (+)‐WAY‐100135. The 5‐HT1D agonist, sumatriptan (0.5 μm) decreased stimulated 5‐HT release to 52 ± 2 % of controls. This decrease was blocked by GR‐127935 but not by WAY‐100635. These results suggest that 5‐HT release in the rat DRN is under the control of 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors.

1 September 1997 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TBT A Bamigbade
T A Bamigbade
CDColin Davidson
Colin Davidson
RLR M Langford
R M Langford
JSJ A Stamford
J A Stamford
Tramadol is an atypical centrally acting analgesic agent with relatively weak opioid receptor affinity in comparison with its antinociceptive efficacy. Evidence suggests that block of monoamine uptake may contribute to its analgesic actions. Therefore, we have examined the actions of (+/-)-tramadol, (+)-tramadol, (-)-tramadol and O-desmethyltramadol (M1 metabolite) on electrically evoked 5-HT efflux and uptake in the dorsal raphe nucleus (DRN) brain slice, measured by fast cyclic voltammetry. Racemic tramadol and its (+)-enantiomer (both 5 mumol litre-1) significantly blocked DRN 5-HT uptake (both P < 0.05) and increased stimulated 5-HT efflux (P < 0.01 (+/-)-tramadol; P < 0.05 (+)-tramadol). The (-)-enantiomer and metabolite, O-desmethyltramadol, were inactive at the concentration tested (5 mumol litre-1). For both (+/-)-tramadol and the (+)-enantiomer, the action on 5-HT efflux preceded an effect on 5-HT uptake, suggesting that uptake block was not the cause of the increased 5-HT efflux and that tramadol might therefore have a direct 5-HT releasing action. This activity, at clinically relevant concentrations, may help to explain the antinociceptive efficacy of tramadol despite weak mu opioid receptor affinity and adds to evidence that tramadol exerts actions on central monoaminergic systems that may contribute to its analgesic effect.

1 December 2012 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
DBDaniel I. Brierley
Daniel I. Brierley
CDColin Davidson
Colin Davidson

1 October 2000 in Trends in Neurosciences
Verified
Journal Article
Closed access
JSJonathan A. Stamford
Jonathan A. Stamford
CDColin Davidson
Colin Davidson
DMDaniel P. McLaughlin
Daniel P. McLaughlin
SHSarah E. Hopwood
Sarah E. Hopwood

1 June 2016 in Neuropharmacology
Verified
Journal Article
Closed access
Maria Antonietta De LucaMaria Antonietta De Luca
Maria Antonietta De Luca
MCM Paola Castelli
M Paola Castelli
BLBarbara Loi
Barbara Loi
APAlessandra Porcu
Alessandra Porcu
MMMariella Martorelli
Mariella Martorelli
GCGaetano Di Chiara
Gaetano Di Chiara